| > Actually, we generally don't even know the real rate of myocarditis in the general population. It's relatively common that someone is admitted to the hospital for another symptom and myocarditis is diagnosed, without the patient even noticing. Yes, but wouldn't we expect this to apply to both groups at the roughly same rate? > As for females, for any age, there is zero statistically significant result for myocarditis included to the vaccine, at all. So for all we know, the vaccine may cause zero myocarditis in females. It's almost certain that further stratification would help. This is not true according to the pre-print (https://www.medrxiv.org/content/10.1101/2021.12.23.21268276v...), page 10. In fact, it shows that Moderna's second dose is associated with higher incidence rate against baseline. Though if we compare with post-covid, there is an overlap in the 95% CI --though IRR for 2nd dose Moderna is higher. > The reason why there was not anymore stratification is because myocarditis due to the vaccine is so rare that if you do stratify it, you cannot come to any conclusion. Fair point. Yes, certainly further stratification would lead to a loss in statistical power and making the point estimates meaningless, but it would be nice to see it in case there is still some point estimates that show statistically significant results because I suspect that the risk of myocarditis goes up inversely with age. |